Cohort | Subtype | Stage | RNA origin | Platform | Result | Reference |
---|---|---|---|---|---|---|
2 cancer | unknown | IV | 1 mL serum | microarray (custom) | Clustered with other cancers and separate from normals | [32] |
9 cancer | Mixed, 60% serous | I-IV | 250uL serum | TaqMan qRT-PCR array | 21 differentially expressed miRNA including miR-21, 92, 93, 29a, 126 | [27] |
4 normal | Â | ---- | Â | Â | Â | Â |
19 cancer | Mixed, 60% serous | I-IV | 250uL serum | TaqMan qRT-PCR Assays (normalizer: miR-142-3p) | Increased in cancer versus normal: miR-21, 92, 93, 29a, 126 | [27] |
11 normal | Â | ---- | Â | Â | Â | Â |
4 cancer | serous | IV | Matched tumor and serum (exosomes from 2.5 mL serum) | microarray (custom) | Similar levels between tumor and serum suggesting a tumor origin for: miR-21, 141, 200a, 200b, 200c, 203, 205 | [15] |
30 cancer | serous | I (10) | Exosomes from 2.5 mL serum | microarray (custom) | Increased in cancer versus benign: miR-21, 141, 200a, 200b, 200c, 203, 205, 214, 215 | [15] |
 |  | II (10) |  |  |  |  |
 |  | III (10) |  |  |  |  |
10 benign | adenoma | ---- | Â | Â | Â | Â |
28 cancer | Serous | II-IV | 500 uL serum | TaqMan qRT-PCR Assays (normalizer: miR-103) | Increased in cancer versus normal: miR-200a, 200b, 200c | This study |
28 normal | Age-matched | ---- | Â | Â | Â | Â |